4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      pH-Dependent Molecular Gate Mesoporous Microparticles for Biological Control of Giardia intestinalis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Giardiasis is a parasitism produced by the protozoa Giardia intestinalis that lives as trophozoite in the small intestine (mainly in the duodenum) attached to the intestinal villus by means of billed discs. The first line treatment is metronidazole, a drug with high bioavailability, which is why to obtain therapeutic concentrations in duodenum, it is necessary to administer high doses of drug to patients with the consequent occurrence of side effects. It is necessary to developed new therapeutical approaches to achieve a local delivery of the drug. In this sense, we have developed gated mesoporous silica microparticles loaded with metronidazole and with a molecular gate pH dependent. In vitro assays demonstrated that the metronidazole release is practically insignificant at acidic pHs, but in duodenum conditions, the metronidazole delivery from the microparticles is effective enough to produce an important parasite destruction. In vivo assays indicate that this microparticulate system allows to increase the concentration of the drug in duodenum and reduce the concentration in plasma avoiding systemic effects. This system could be useful for other intestinal local treatments in order to reduce doses and increase drug availability in target tissues.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release.

          Mesoporous silica nanoparticles (MSNs) are introduced as chemically and thermally stable nanomaterials with well-defined and controllable morphology and porosity. It is shown that these particles possess external and internal surfaces that can be selectively functionalized with multiple organic and inorganic groups. On the basis of these characteristics, the biocompatibility of silica, and their efficient uptake by mammalian cells, MSNs are proposed as the basis of nanodevices for the controlled release of drugs and genes into living cells.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Treatment of giardiasis.

            Giardia lamblia is both the most common intestinal parasite in the United States and a frequent cause of diarrheal illness throughout the world. In spite of its recognition as an important human pathogen, there have been relatively few agents used in therapy. This paper discusses each class of drugs used in treatment, along with their mechanism of action, in vitro and clinical efficacy, and side effects and contraindications. Recommendations are made for the preferred treatment in different clinical situations. The greatest clinical experience is with the nitroimidazole drugs, i.e., metronidazole, tinidazole, and ornidazole, which are highly effective. A 5- to 7-day course of metronidazole can be expected to cure over 90% of individuals, and a single dose of tinidazole or ornidazole will cure a similar number. Quinacrine, which is no longer produced in the United States, has excellent efficacy but may be poorly tolerated, especially in children. Furazolidone is an effective alternative but must be administered four times a day for 7 to 10 days. Paromomycin may be used during early pregnancy, because it is not systematically absorbed, but it is not always effective. Patients who have resistant infection can usually be cured by a prolonged course of treatment with a combination of a nitroimidazole with quinacrine.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Gastrointestinal uptake of biodegradable microparticles: effect of particle size.

              To investigate the effect of microparticle size on gastrointestinal tissue uptake. Biodegradable microparticles of various sizes using polylactic polyglycolic acid (50:50) co-polymer (100 nm, 500 nm, 1 micron, and 10 microns) and bovine serum albumin as a model protein were formulated by water-in-oil-in-water emulsion solvent evaporation technique. The uptake of microparticles was studied in rat in situ intestinal loop model and quantitatively analyzed for efficiency of uptake. In general, the efficiency of uptake of 100 nm size particles by the intestinal tissue was 15-250 fold higher compared to larger size microparticles. The efficiency of uptake was dependent on the type of tissue, such as Peyer's patch and non patch as well as on the location of the tissue collected i.e. duodenum or ileum. Depending on the size of microparticles, the Peyer's patch tissue had 2-200 fold higher uptake of particles than the non-patch tissue collected from the same region of the intestine. Histological evaluation of the tissue sections demonstrated that 100 nm particles were diffused throughout the submucosal layers while the larger size nano/microparticles were predominantly localized in the epithelial lining of the tissue. There is a microparticle size dependent exclusion phenomena in the gastrointestinal mucosal tissue with 100 nm size particles showing significantly greater tissue uptake. This has important implications in designing of nanoparticle-based oral drug delivery systems, such as an oral vaccine system.
                Bookmark

                Author and article information

                Journal
                Pharmaceutics
                Pharmaceutics
                pharmaceutics
                Pharmaceutics
                MDPI
                1999-4923
                13 January 2021
                January 2021
                : 13
                : 1
                : 94
                Affiliations
                [1 ]Department of Engineering, Pharmacokinetics and Pharmaceutical Technology Area, Miguel Hernandez University, Elche. San Juan Campus, 03550 San Juan, Spain; isabel.gonzalez@ 123456umh.es (I.G.-A.); cucunica@ 123456hotmail.com (V.V.); barbarasanchezdengra@ 123456gmail.com (B.S.-D.); alejandroruizpicazo@ 123456gmail.com (A.R.-P.); mbermejo@ 123456goumh.umh.es (M.B.)
                [2 ]Instituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico, Universitat Politècnica de València and Universitat de València, Camino de Vera s/n, 46022 Valencia, Spain; carmencollmerino@ 123456gmail.com (C.C.); elazgi@ 123456upvnet.upv.es (E.A.); fsanceno@ 123456upvnet.upv.es (F.S.); rmaez@ 123456qim.upv.es (R.M.-M.)
                [3 ]CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), 46022 Valencia, Spain
                [4 ]Unidad Mixta UPV-CIPF de Investigación en Mecanismos de Enfermedades y Nanomedicina, Universitat Politècnica de València, Centro de Investigación Príncipe Felipe, C/Eduardo Primo Yúfera 3, 46012 Valencia, Spain
                [5 ]Unidad Mixta de Investigación en Nanomedicina y Sensores, Universitat Politècnica de València, IIS La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain
                [6 ]Departamento de Farmacia, Facultad de Ciencias de la Salud, Universidad Cardenal Herrera-CEU, C/Santiago Ramón y Cajal, s/n, Alfara del Patriarca, 46115 Valencia, Spain; mda_3000@ 123456yahoo.es
                Author notes
                [* ]Correspondence: marta.gonzalez@ 123456umh.es
                Author information
                https://orcid.org/0000-0002-1685-142X
                https://orcid.org/0000-0003-2159-4314
                https://orcid.org/0000-0003-0361-3876
                https://orcid.org/0000-0001-5022-0544
                https://orcid.org/0000-0001-5873-9674
                Article
                pharmaceutics-13-00094
                10.3390/pharmaceutics13010094
                7828499
                33451061
                c5025f26-f3fd-4ba4-98bf-e11167c75cf6
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 30 November 2020
                : 07 January 2021
                Categories
                Article

                mesoporous microparticles,g. intestinalis,molecular gate,targeted drug delivery,oral administration

                Comments

                Comment on this article